Review Article
N-Acetylcysteine for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
Table 2
Characteristics of included studies: baseline characteristics systematic reviews of randomized controlled trials.
| |
Characteristics | Among women with PCOS | Among women with clomiphene resistant PCOS | | Salehpour et al. 2009 [17] | Gayatri et al. 2010 [28] | Oner and Muderris 2011 [18] | Salehpour et al. 2012 [19] | Rizk et al. 2005 [20] | Elnashar et al. 2007 [14] | Hashim et al. 2010 [21] | Nasr 2010 [22] |
| | | NAC/placebo | NAC/metformin | NAC/metformin | NAC/placebo | NAC/placebo | NAC/metformin | NAC/metformin | NAC/placebo | | Total randomized, | 46 | 115 | 100 | 180 | 153 | 64 | 192 | 60 | | Randomised, | 46 | 56/59 | 50 /50 | 90/90 | NA | 32/32 | 95/97 | 30/30 | | Completed, | 36 | 50/50 | 45/31 | 82/85 | 75/75 | 30/31 | 97/95 | 30/30 | | Total, | 36 | 100 | 76 | 167 | 150 | 61 | 192 | 60 | | Attrition rate | 21.7% | 13% | 24% | 7% | 2% | 4.7% | 0% | 0% | | Baseline Characteristics | | | | | | | | | | Age, years | 27.2 (5.4)
27.8 (6.1) | 22.6 (3.8);
23.2 (4.1) | 23.7 (4.4);
22.6 (4.8) | 27.22 (3.32);
27.41 (3.41) | 28.9 (4.7);
28.4 (5.7) | 27.33 (3.35);
26.73 (5.36) | 27.3 (2.6);
26.8 (2.2) | 28.4 (4.2);
29.2 (3.7) | | Weight, kg | 74.1 (11.7)
74.1 (13.2) | 70.5 (3.45);
69.8 (8.32) | NA | NA | 101.3 (12.4);
99.2 (12.3) | NA | NA | NA | | BMI, kg/m2 | 29.5 (4.1)
29.5 (4.4) | 26.54 (2.35);
27.28 (3.25) | 23 (4.6);
24.3 (6.2) | 26.78 (2.24);
26.67 (2.01) | 30.5 (2.6);
30.1 (3.1) | 25.8 (0.94);
26.8 (1.52) | 26.6 (2.2);
26.3 (2.3) | 28.6 (3.7);
29.1 (4.2) | | Amenorrhea patients (%) | 2 (11.1%)
2 (11.1%) | 4 (8%);
4 (8%) | NA | NA | NA | NA | 6 (6.3%);
7 (7.2%) | 5 (17%);
6 (20%) | | Oligomenorrhea, (%) | NA | 29 (58%);
30 (60%) | NA | NA | NA | 76.7 (23);
77.4 (24) | 89 (93.7%);
90 (92.8%) | NA | | Hirsutism, (%) | 11 (61.1%)
10 (55.6%) | 2 (4%);
3 (6%) | NA | NA | NA | NA | NA | 16 (53%);
18 (60%) | | Acne, (%) | 5 (27.8%)
5 (27.8%) | 1 (2); 2 (4) | NA | NA | NA | NA | NA | NA | | Duration of Infertility, mean (SD) | 4.5 (2.2)
4.2 (3.3) | 10 (20);
8 (16) | NA | 4.39 (1.96);
4.45 (1.94) | 5 (2.9);
4.4 (2.6) | NA | 4.5 (1.2);
4.7 (1.3) | 5.3 (1.9);
4.9 (2.1) | | Testosterone level, nmol/dL, mean (SD) | 0.91 (0.48)
1.01 (0.45) | 1.55 (0.29);
1.65 (0.24) | 80.8 (41.1);
86.1 (48.4) | NA | NA | 98.27 (31.5);
106.5 (44.6) | 1.06 (0.27);
1.03 (0.31) | NA | | FPG, mg/dL, mean (SD) | 95.6 (10.9)
96.8 (27.7) | 88.53 (5.14);
87.65 (4.34) | 88.5 (6.8);
88.9 (7.4) | NA | 81.9 (12.6);
85.9 (14.1) | 83.3 (8.8);
85.9 (9.4) | 91.3 (1.5);
89.6 (1.4) | NA | | HOMA-IR | 5.22 (5.58);
4.9 (4.2) | 5.52 (1.35);
5.42 (1.36) | 4.5 (1.2);
4.3 (0.9) | NA | NA | NA | NA | NA |
|
|
